IMV:CC News and Press, Imv Inc.

IMV Inc. (the “ Company ” or “ IMV ”) announces today that it has accepted an offer (the “ Offer ”) from IMV’s largest secured creditors (the “ Secured Lenders ”), pursuant to which IMV and its subsidiary, Immunovaccin...

IMV Inc. (the “ Company ” or “ IMV ”), recently announced an update on the Sales and Investment Solicitation Process (the “ SISP ”) implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the “...

IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...

Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...

IMV Inc. (the “ Company ” or “ IMV ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, announced today tha...

IIROC Trading Halt - IMV Canada NewsWire TORONTO , May 1, 2023 /CNW/ - The following issues have been halted by IIROC: Company: IMV Inc. TSX Symbol: IMV All Issues: Yes Reason: Pending News Halt Time (ET): 8:00 AM IIROC can mak...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board o...

Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platform Observed multiple complete clinical responses in relapsed/refractory DLBCL and expect to complete enrollment of stage one in the VITALIZE study in Q2 2023...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to...

Early analysis reveals clinically meaningful activity in refractory DLBCL patients Multiple confirmed complete responses observed in heavily pre-treated patients No adverse safety and tolerability signal reported, consistent with previous clinical trials IMV Inc. (Nasdaq...